- Éva Cochery-Nouvellon1,
- Érick Mercier1,
- Sylvie Bouvier1,
- Jean-Pierre Balducchi2,
- Isabelle Quéré3,
- Antonia Perez-Martin4,
- Eve Mousty5,
- Vincent Letouzey5 and
- Jean-Christophe Gris1,*
- 1 Department of Hematology, University Hospital, Nîmes, France;
- 2 Department of Internal Medicine, University Hospital, Nîmes, France;
- 3 Department of Vascular Medicine and Internal Medicine, University Hospital, Montpellier, France;
- 4 Department of Vascular Medicine, University Hospital, Nîmes, France;
- 5 Department of Gynecology and Obstetrics, University Hospital, Nîmes, France
- ↵* Corresponding author; email:
The prognostic value of angiogenic factors in newly pregnant women with obstetric antiphospholipid syndrome has not been documented. We observed 513 obstetric antiphospholipid syndromes who experienced three consecutive spontaneous abortions before the 10th week of gestation or one fetal loss at or beyond the 10th week. We assessed the plasma concentrations of the proangiogenic factor placenta growth factor and of the antiangiogenic factor soluble fms-like tyrosine kinase-1 on the eve and on the 4th day of the low-molecular weight heparin-low dose aspirin treatment. Placenta growth factor and fms-like tyrosine kinase-1 plasma concentrations evidenced marked increases. Treatment-associated variations of placenta growth factor and of soluble fms-like tyrosine kinase-1 were antagonist risk factors for placenta-mediated complications and for severe placenta-mediated complications; for fetal death, stillbirth and neonatal death. The ratio between placenta growth factor increase and soluble fms-like tyrosine kinase-1 was a summary variable whose best cut-off values (1.944.10-2) had high negative predictive values for placenta-mediated complications (0.918) and may be used to help ruling out the development of placenta-mediated complications in evolutive pregnancies after 19 completed weeks. The early variations of placenta growth factor and soluble fms-like tyrosine kinase-1 concentrations in newly pregnant obstetric antiphospholipid syndromes may help detecting patients at low risk of placenta-mediated complications.
- Received August 23, 2016.
- Accepted January 20, 2017.
- Copyright © 2017, Ferrata Storti Foundation